A European scoring system successfully predicts bladder cancer risks
Bladder cancer that has not spread deep into the muscle wall is common but unpredictable. Doctors call this non-muscle-invasive bladder cancer. Even within specific types of this disease, such as high-grade tumors that look aggressive under a microscope, some patients heal well while others see their cancer return or worsen. To help predict who faces the biggest risks, medical experts in Europe created a tool in 2021 to sort patients into different risk categories. Recently, researchers put that tool to the test to see if it actually works in real clinical settings. The research team looked back at the medical records of 316 patients. They used the European classification system to group these individuals as having either an intermediate risk or a high risk based on factors like age, the number of tumors, and tumor size. The tool proved to be highly effective. Patients placed in the high-risk group were much more likely to experience a cancer relapse or see their disease progress compared to those in the intermediate-risk group. For example, over 97 percent of intermediate-risk patients went three years without their cancer worsening, compared to about 91 percent of high-risk patients. While the tool was excellent at predicting if the cancer would return or grow, it did not predict overall life expectancy. Patients in both risk groups had similar chances of staying alive, avoiding bladder removal surgery, and surviving the cancer itself. The researchers note a few limitations to their findings, pointing out that the study looked back at past data rather than tracking new patients, relied on a moderate group of 316 people, and followed their health for an average of just 36 months.
